Literature DB >> 9801871

Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy.

J E Taylor1, N H Thomas, C M Lewis, S J Abbs, N R Rodrigues, K E Davies, C G Mathew.   

Abstract

Childhood-onset autosomal recessive spinal muscular atrophy (SMA) is associated with absence of the telomeric survival motor neuron gene (SMNt) in most patients, and deletion of the neuronal apoptosis inhibitory protein (NAIP) gene in the majority of severely affected patients. Analysis of SMNt has been complicated by the existence of a centromeric copy, SMNc, which is almost identical to SMNt but which can be distinguished from it by restriction enzyme analysis. In this study 143 SMA patients have been genotyped for the presence or absence of the SMNt, SMNc and NAIP genes, and the data correlated with quantifiable clinical variables. Although a significant correlation was observed between the presence or absence of the NAIP gene and the severity of the clinical phenotype in SMA patients generally, there was no difference in age of onset or survival in type I patients with the NAIP+ or NAIP- genotype. Fluorimetric PCR analysis of SMNc gene dosage in 57 patients homozygous for the absence of the SMNt gene but in whom the NAIP gene was present showed a highly significant correlation between SMNc copy number and SMA subtype, and between SMNc copy number and both age of onset and length of survival. The data provide strong statistical support for the emerging consensus that the clinical phenotype in SMA is directed primarily by the level of functional SMN protein. The lower SMNc copy number in type I patients in whom the NAIP gene is present suggests that the SMNt gene is removed by deletion in the majority of such patients, rather than by gene conversion as is the case in SMA types II and III.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801871     DOI: 10.1038/sj.ejhg.5200210

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  22 in total

1.  Spinal muscular atrophy--type I.

Authors:  M K M Hardart; R D Truog
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

2.  Interaction between alpha-COP and SMN ameliorates disease phenotype in a mouse model of spinal muscular atrophy.

Authors:  Sara K Custer; Jacob W Astroski; Hong Xia Li; Elliot J Androphy
Journal:  Biochem Biophys Res Commun       Date:  2019-05-03       Impact factor: 3.575

3.  Study of survival of motor neuron (SMN) and neuronal apoptosis inhibitory protein (NAIP) gene deletions in SMA patients.

Authors:  Akanchha Kesari; Usha Kant Misra; Jayantee Kalita; Vijay Nath Mishra; Sunil Pradhan; Siddramappa Jagdish Patil; Shubha Rajender Phadke; Balraj Mittal
Journal:  J Neurol       Date:  2005-03-18       Impact factor: 4.849

4.  Differential regulation of the SMN2 gene by individual HDAC proteins.

Authors:  Matthew C Evans; Jonathan J Cherry; Elliot J Androphy
Journal:  Biochem Biophys Res Commun       Date:  2011-09-06       Impact factor: 3.575

5.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

Authors:  Markus Feldkötter; Verena Schwarzer; Radu Wirth; Thomas F Wienker; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2001-12-21       Impact factor: 11.025

6.  A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.

Authors:  Xingxing Wu; Shu-Huei Wang; Junjie Sun; Adrian R Krainer; Yimin Hua; Thomas W Prior
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

7.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

8.  A natural history study of late onset spinal muscular atrophy types 3b and 4.

Authors:  S Piepers; L H van den Berg; F Brugman; H Scheffer; M Ruiterkamp-Versteeg; B G van Engelen; C G Faber; M de Visser; W-L van der Pol; J H J Wokke
Journal:  J Neurol       Date:  2008-06-30       Impact factor: 4.849

9.  A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.

Authors:  Haiyan Zhou; Narinder Janghra; Chalermchai Mitrpant; Rachel L Dickinson; Karen Anthony; Loren Price; Ian C Eperon; Stephen D Wilton; Jennifer Morgan; Francesco Muntoni
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695

10.  The spinal muscular atrophy disease protein SMN is linked to the Golgi network.

Authors:  Chen-Hung Ting; Hsin-Lan Wen; Hui-Chun Liu; Hsiu-Mei Hsieh-Li; Hung Li; Sue Lin-Chao
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.